iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Dr Reddy’s to market Ingenus' cancer treatment injection in USA

13 Jun 2024 , 03:08 PM

Dr Reddy’s Laboratories Ltd announced on Wednesday that it has inked a licensing agreement with US-based Ingenus Pharmaceuticals, LLC, to commercialise Cyclophosphamide injection, which is used to treat cancer. Dr Reddy’s Laboratories Inc, the company’s wholly-owned subsidiary, and Ingenus Pharmaceuticals, LLC have signed a license agreement, according to a regulatory filing from Dr Reddy’s Laboratories Ltd (DRL).

Dr Reddy’s Laboratories Inc (Dr Reddy’s USA) has licensed from Ingenus the exclusive rights to commercialise Cyclophosphamide injection in strengths of 500 mg/2.5mL; 1g/5mL; and 2g/10mL in the United States, it added.

According to the filing, Dr. Reddy’s USA will commercialise the Cyclophosphamide injection in the United States and will pay Ingenus 50% of the estimated profit share, with no further consideration payable.

According to IQVIA, the sales of the aforementioned Ingenus product for the preceding 12 months ended March 2024 totaled USD 51.8 million.

According to the company, the parties will sign a commercial supply agreement under which Ingenus will deliver the product to Dr. Reddy’s USA.

Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s) is a pharmaceutical company that produces and promotes generic formulations, active pharmaceutical ingredients (APIs), biosimilars, and branded medicines. The company’s generic medications are used to treat gastrointestinal problems, various cancer types, pain, cardiovascular diseases, central nervous system disorders, infectious diseases, and pediatric illnesses.

At around 10.54 AM, Dr Reddy’s was trading flat at ₹6,055.70, against the previous close of ₹6,060.05 on NSE. The counter touched an intraday high and low of ₹6,119.90, and ₹6,031.50, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/

 

Related Tags

  • Dr Reddy's agreement
  • Dr Reddy's shares
  • Dr Reddy's Updates
  • Dr Reddys
  • Dr Reddys share price
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.